Background {#section5-2042098619838138}
==========

Osteoporosis and associated fractures are a public health issue of growing importance with a significant impact on healthcare utilization, morbidity and mortality. The incidence of osteoporosis increases with age, and the proportion of old and very old people is steadily rising.^[@bibr1-2042098619838138],[@bibr2-2042098619838138]^ Consequently, the proportion of patients treated with anti-osteoporotic drugs is rising too.

Several pharmacological therapies are available for osteoporosis prevention and treatment, and, in Italy, bisphosphonates (BPs) are most commonly used, followed by strontium ranelate (SR).

While for both treatments the efficacy in reducing fracture risk is well established in randomized controlled trials,^[@bibr3-2042098619838138][@bibr4-2042098619838138][@bibr5-2042098619838138][@bibr6-2042098619838138][@bibr7-2042098619838138][@bibr8-2042098619838138][@bibr9-2042098619838138]--[@bibr10-2042098619838138]^ there is conflicting evidence about BP use and cardiovascular risk.

An increased risk of atrial fibrillation (AF) in BP users was reported by several clinical trials^[@bibr3-2042098619838138],[@bibr11-2042098619838138][@bibr12-2042098619838138][@bibr13-2042098619838138]--[@bibr14-2042098619838138]^ and a meta-analysis,^[@bibr15-2042098619838138]^ while other authors did not confirm these findings.^[@bibr5-2042098619838138],[@bibr6-2042098619838138],[@bibr16-2042098619838138],[@bibr17-2042098619838138]^

Conflicting results are also coming from observational research. While several studies suggest an increased risk of acute myocardial infarction (AMI)^[@bibr18-2042098619838138]^ and AF among BP users,^[@bibr13-2042098619838138],[@bibr14-2042098619838138],[@bibr19-2042098619838138][@bibr20-2042098619838138][@bibr21-2042098619838138]--[@bibr22-2042098619838138]^ other studies did not find any association between exposure to BPs and increased cardiovascular risk.^[@bibr23-2042098619838138][@bibr24-2042098619838138][@bibr25-2042098619838138]--[@bibr26-2042098619838138]^ In one study, the increased risk was limited to AMI and only for longer exposure to BPs.^[@bibr27-2042098619838138]^

Some authors even suggest a possible risk reduction of AMI and other cardiovascular diseases.^[@bibr28-2042098619838138][@bibr29-2042098619838138][@bibr30-2042098619838138]--[@bibr31-2042098619838138]^

A series of potential mechanisms by which BPs might increase AF risk have been proposed, including an activated inflammatory state, altered electrolytes impacting cardiac conduction, antiangiogenic effects, and long-term atrial structural changes.^[@bibr28-2042098619838138],[@bibr32-2042098619838138],[@bibr33-2042098619838138]^

On the basis of the disparate findings reported in trials, observational studies and meta-analyses, some authors recommend that patients with pre-existing risk factors for AF should be monitored when they start BP treatment.^[@bibr34-2042098619838138],[@bibr35-2042098619838138]^

The I-GrADE (Italian Group for Appropriate Drug Prescription in the Elderly) project, a recent Italian multicentre programme focussed on inappropriate pharmacological treatments in older adults affected by cardiovascular disease and other chronic comorbidities. A systematic literature review, performed by the group, identified BP use in patients with cardiovascular conditions as being potentially inappropriate.^[@bibr36-2042098619838138]^ Therefore, in line with the commitment of the I-GrADE consortium, the aim of the present study was to investigate the hypothesis of increased risk of AF and acute cerebrovascular/cardiovascular (CCV) events, in particular acute ischaemic heart disease, heart failure, arrhythmia and acute cerebrovascular events, in a large cohort of older adults with cardiovascular diseases and exposed to BPs in a real-world setting, compared with other anti-osteoporotic treatments and no treatment. Along with the other studies performed in the context of the I-GrADE research programme, our results might contribute to define a reliable list of indicators of inappropriate drug treatment and improve drug prescribing to older adults affected by cardiovascular diseases.

Methods {#section6-2042098619838138}
=======

Setting {#section7-2042098619838138}
-------

The present study was performed in the context of the multicentre I-GrADE project, funded by the Italian Medicines Agency, which has been described in detail elsewhere.^[@bibr35-2042098619838138]^ Briefly, healthcare data from three Italian regions (Lazio, Lombardy, and Tuscany) and two local health units (Caserta and Treviso), were retrieved for patients aged 65 years or older and discharged from hospital with a diagnosis of acute CCV disease between 2008 and 2012. The database comprises information from administrative claims including demographic data, mortality, hospital discharge records with diagnoses coded using the 9th version of the International Classification of Diseases, with clinical modification (ICD-9 CM), and outpatient drug prescription claims, coded in the Anatomic Therapeutic and Chemical (ATC) classification system. Further details of the cohort inclusion and exclusion criteria have been reported previously.^[@bibr37-2042098619838138],[@bibr38-2042098619838138]^

Study population {#section8-2042098619838138}
----------------

We performed two nested case-control studies to evaluate the relationship between anti-osteoporotic drug use and the risk of AF (referred to hereafter as 'the AF study') and acute CCV events (referred to hereafter as 'the CCV study'); [Figure 1](#fig1-2042098619838138){ref-type="fig"} summarizes the main characteristic of the study design. The study cohort consisted of all patients aged 65 years and over, discharged from hospitals after a CCV event (heart failure, cerebrovascular disease or ischaemic heart disease) between 1 January 2008 and 31 December 2011 (index admission). Exclusion criteria were: less than 12 months of follow-back for comorbidities assesment, treatment with anti-osteoporotic drugs (BPs, SR, raloxifene, teriparatide, calcitonin, denosumab, and oestrogens) in the year before the index admission, and fewer than 30 days of individual follow up after the index admission. The length of the wash-out period was driven by data availability.

![Study design.\
AF, atrial fibrillation; CCV, cerebrovascular/cardiovascular.](10.1177_2042098619838138-fig1){#fig1-2042098619838138}

Follow up {#section9-2042098619838138}
---------

Follow up started on the index date and ended at the occurrence of the study outcome, death, switch to an alternative osteoporosis treatment, or disenrollment from the regional healthcare system, whichever came first.

Nested case-control studies {#section10-2042098619838138}
---------------------------

Overall, two mutually exclusive nested case-control studies were performed within the study cohort. In the AF study, cases were defined as patients with a hospital admission having a primary diagnosis for AF (ICD-9-CM 427.3) occurring after the index hospital admission. In the CCV study, the outcome of interest was a composite endpoint of acute CCV events \[acute ischaemic heart disease (ICD-9-CM 410-411), arrhythmia (ICD-9-CM 427.x), acute cerebrovascular events (ICD-9-CM 430-432, 433.x1, 434.x1, 436), and heart failure (ICD-9-CM 428.X)\]. For both studies, events occurring within 30 days after the index date were not considered, as they might have been related to the index admission. A total of four controls were matched to each case by sex, 5-year age group and duration of follow up. Controls were chosen among patients with no hospital admission for the specific outcome of interest within the case follow-up time, regardless of hospitalizations for other causes.

Exposure {#section11-2042098619838138}
--------

The exposure of interest was treatment with anti-osteoporotic drugs, considering three different groups: (1) BPs (e.g. clodronic acid, pamidronic acid, alendronic acid, ibandronic acid, risedronic acid, zoledronic acid, neridronic acid), (2) SR and (3) other anti-osteoporotic drugs (e.g. raloxifene, teriparatide, calcitonin, denosumab, oestrogens), using no anti-osteoporotic treatment as a reference group. Exposures were mutually exclusive, and the very few patients switching between treatments during follow up were excluded. Overall, three exposure measures were applied: no use *versus* ever use, defined as at least one prescription during the follow up; the proportion of days covered (PDC), calculated as the number of defined daily doses (DDDs) available to the patient over the days of patient-level follow up, and divided into three categories (\<20%, 20--80%, \>80%); time between the date of the last prescription prior to the outcome and the outcome, distinguishing between current users (⩽90 days before the event/end of follow up), recent users (91--180 days before the event/end of follow up), and distant users (\>180 days before the event/end of follow up) in line with a previous Italian study.^[@bibr21-2042098619838138]^

Covariates {#section12-2042098619838138}
----------

Several potential confounders were taken into account: the CCV condition at enrolment, comorbidities retrieved through hospital admissions during the 2 years before the index admission, both, as primary and secondary diagnoses and drug use in the year before index admission ([Table 1](#table1-2042098619838138){ref-type="table"}) was retrieved from drug claims databases. The choice of different time windows was driven by data availability. Comorbidities and concomitant medications were selected through a stepwise approach. Crude and adjusted association measures were estimated using conditional logistic regression models.

###### 

Comorbidities and drug use prior to index admission.

![](10.1177_2042098619838138-table1)

  Condition                                                     ICD-9-CM CODE
  ------------------------------------------------------------- ----------------------------------------------------------------------------
  Cancer                                                        140.0--208.9, V10
  Diabetes                                                      250.0--250.9
  Lipid metabolism disturbances                                 272
  Obesity                                                       278
  Blood disorders                                               280--285, 288, 289
  Hypertension                                                  401--405
  Previous myocardial infarction                                410, 412
  Other forms of ischaemic heart disease                        411, 413, 414
  Heart failure                                                 428
  Ill-defined descriptions and complications of heart disease   429
  Rheumatic heart disease                                       391, 393--398
  Cardiomyopathy                                                425
  Acute endocarditis and myocarditis                            421, 422
  Other heart conditions                                        745, V15.1, V42.2, V43.2, V43.3, V45.0
  Conduction disturbances                                       426
  Arrhythmias                                                   427
  Cerebrovascular disease                                       430--438
  Vascular disease                                              440--448, 557
  Chronic obstructive pulmonary disease                         491--492, 494, 496
  Chronic renal disease                                         582--583, 585--588
  Chronic diseases (liver, pancreas, intestine)                 571--572, 577.1--577.9, 555, 556
  Previous coronary artery bypass graft                         36.1, V45.81
  Previous coronary angioplasty                                 00.66, 36.0, V45.82
  Cerebral revascularization procedures                         00.61, 00.62, 38.01, 38.02, 38.11, 38.12, 38.31, 38.32
  Other cardiac operations                                      35, 37.0, 37.1, 37.3, 37.4, 37.5, 37.6, 37.9
  Other vascular operations                                     38--39.5, excluding: 38.01, 38.02, 38.5, 38.11, 38.12, 38.31, 38.32, 38.93
  Thyroid disease                                               240--246
  **Drug class**                                                **ATC code**
  Cardiac therapy                                               C01
  Antihypertensives                                             C02
  Diuretics                                                     C03
  Beta-adrenergic antagonist                                    C07
  Calcium channel blockers                                      C08
  Acetylcholinesterase inhibitors                               C09
  Lipid-modifying agents                                        C10
  Oral anticoagulants                                           B01AA, B01AE, B01AF
  Drugs used in diabetes                                        A10A, A10B
  Platelet aggregation inhibitors, excluding heparin            B01AC
  Corticosteroids for systemic use                              H02
  Thyroid therapy                                               H03

Sensitivity analyses {#section13-2042098619838138}
--------------------

A total of three sensitivity analyses were performed. In the first analysis, we excluded patients who spent more than 50% of their follow-up time in hospital, accounting for the lack of information on drug treatment in hospital. Secondly, we used the cardiovascular diagnosis at enrolment as a matching variable, rather than as a potential confounder, and thirdly, we considered BP users only and compared different adherence patterns (PDC \< 20%, 20--80%, \>80%).

All the analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA).

Results {#section14-2042098619838138}
=======

Among over 800,000 patients discharged from hospital with a CCV diagnosis during the study period, 657,246 were enrolled in the study cohort ([Figure 2](#fig2-2042098619838138){ref-type="fig"}). More than half of the study population were men and the mean age was 78.3 ±7 years. The most frequent conditions at enrolment were heart failure, stroke, AMI and AF. During follow up, 28,090 patients were diagnosed with AF (rate: 1.8/100 person years), and 157,031 patients were hospitalized for the combined CCV outcome (rate: 11.3/100 person years) ([Figure S1](https://journals.sagepub.com/doi/suppl/10.1177/2042098619838138) and [S2](https://journals.sagepub.com/doi/suppl/10.1177/2042098619838138)). Among the 30,756 patients with anti-osteoporotic treatment, BPs were the most commonly prescribed (70.0%), followed by SR (28.0%). All other agents were much less commonly used.

![Flow chart cohort enrolment.\
AF, atrial fibrillation.](10.1177_2042098619838138-fig2){#fig2-2042098619838138}

The main characteristics of cases and controls in the two studies are reported in [Table 2](#table2-2042098619838138){ref-type="table"}. In the AF study, cases were more likely to have had a previous episode of AF (12.3% *versus* 4.6%) or arrhythmia (72.4% *versus* 42.0%) and were more frequently treated with cardiac therapy and oral anticoagulant (47.0% *versus* 34.0% and 31.0% *versus* 14.4% respectively). In the CCV study, cases were more commonly treated with diuretics and cardiac therapy in the year before the enrolment in the cohort, compared with controls.

###### 

AF and CCV study: characteristics of cases and controls.

![](10.1177_2042098619838138-table2)

                                                                   AF study   CCV study                                              
  ---------------------------------------------------------------- ---------- ----------- -------- ------ --------- ------ --------- ------
  ***Main diagnosis at index admission***                                                                                            
  Acute ischaemic heart disease                                    1775       6.3         14,013   12.5   6124      3.9    22,674    3.6
  Arrhythmia                                                       10,739     38.2        11,861   10.6   4826      3.1    20,471    3.3
  Stroke                                                           1043       3.7         10,176   9.1    10,737    6.8    60,003    9.6
  Heart failure                                                    3770       13.4        11,046   9.8    30,760    19.6   61,620    9.8
  Atrial fibrillation                                              9663       34.4        8124     7.2    16,173    10.3   42,509    6.8
  ***Comorbidities (any position, 24 months before enrolment)***                                                                     
  Cancer                                                           2032       7.2         9890     8.8    12,833    8.2    54,988    8.8
  Diabetes                                                         4180       14.9        21,375   19     35,541    22.6   110,168   17.5
  Lipid metabolism disturbances                                    2317       8.2         11,816   10.5   12,487    8      55,111    8.8
  Obesity                                                          696        2.5         2686     2.4    3866      2.5    11,974    1.9
  Blood disorders                                                  1903       6.8         8744     7.8    16,145    10.3   55,223    8.8
  Hypertension                                                     12,270     43.7        47,282   42.1   67,576    43     261,361   41.6
  Previous AMI                                                     2723       9.7         17,315   15.4   27,207    17.3   86,039    13.7
  Other forms of ischaemic heart disease (no index)                2056       7.3         7902     7      15,616    9.9    38,502    6.1
  Heart failure (no index)                                         1337       4.8         4007     3.6    12,929    8.2    19,731    3.1
  AF (no index)                                                    3447       12.3        5170     4.6    13,166    8.4    27,332    4.4
  Ill-defined descriptions and complications of heart disease      1057       3.8         3617     3.2    7471      4.8    18,529    3
  Rheumatic heart disease                                          882        3.1         2224     2      4800      3.1    11,770    1.9
  Cardiomyopathy                                                   1444       5.1         4072     3.6    9715      6.2    18,338    2.9
  Acute endocarditis and myocarditis                               32         0.1         157      0.1    255       0.2    684       0.1
  Other heart conditions                                           1625       5.8         4488     4      9715      6.2    22,528    3.6
  Conduction disturbances                                          956        3.4         3627     3.2    6431      4.1    20,753    3.3
  Arrhythmias                                                      20,347     72.4        35,973   32     67,876    43.2   205,166   32.7
  Cerebrovascular disease                                          4317       15.4        37,140   33.1   40,153    25.6   223,523   35.6
  Vascular disease                                                 1777       6.3         8668     7.7    13,683    8.7    45,826    7.3
  COPD                                                             2723       9.7         12,243   10.9   22,433    14.3   71,442    11.4
  Chronic renal disease                                            2071       7.4         8305     7.4    19,875    12.7   47,877    7.6
  Chronic disease (liver, pancreas, intestine)                     623        2.2         2962     2.6    3829      2.4    15,122    2.4
  Previous CABG                                                    1055       3.8         4718     4.2    7030      4.5    21,784    3.5
  Previous PCI                                                     2228       7.9         14,891   13.3   17,815    11.3   67,486    10.7
  Cerebral revascularization procedures                            311        1.1         3595     3.2    2443      1.6    17,989    2.9
  Other cardiac operations                                         1668       5.9         4208     3.7    6763      4.3    18,553    3
  Other vascular operations                                        1156       4.1         5961     5.3    8196      5.2    30,760    4.9
  Thyroid disease                                                  1597       5.7         4367     3.9    7106      4.5    23,705    3.8
  ***Drug use (12 months before enrolment)***                                                                                        
  Cardiac therapy                                                  13,207     47          38,157   34     73,220    46.6   214,825   34.2
  Antihypertensives                                                2618       9.3         9079     8.1    14,501    9.2    47,820    7.6
  Diuretics                                                        11,126     39.6        37,808   33.6   77,093    49.1   219,922   35
  Beta-adrenergic antagonist                                       12,134     43.2        39,986   35.6   61,316    39     202,665   32.3
  Calcium channel blockers                                         10,096     35.9        36,049   32.1   55,541    35.4   198,293   31.6
  ACE inhibitors                                                   19,571     69.7        72,813   64.8   110,409   70.3   399,383   63.6
  Lipid-modifying agents                                           9363       33.3        40,622   36.2   54,574    34.8   200,799   32
  Oral anticoagulants                                              8721       31          16,169   14.4   32,274    20.6   85,088    13.5
  Drugs used in diabetes                                           5231       18.6        25,889   23     42,501    27.1   131,648   21
  Platelet aggregation inhibitors (excluding heparin)              13,694     48.8        58,529   52.1   85,632    54.5   326,715   52
  Corticosteroids for systemic use                                 3794       13.5        15,196   13.5   23,481    15     87,067    13.9
  Thyroid therapy                                                  1432       5.1         4216     3.8    6762      4.3    22,623    3.6

ACE, acetylcholinesterase; AF, atrial fibrillation; CABG, Coronary Artery Bypass Graft; CCV, acute cerebrovascular/cardiovascular events; COPD, chronic obstructive pulmonary disease; PCI, Percutaneous Coronary Intervention.

[Table 3](#table3-2042098619838138){ref-type="table"} reports the results on the association between use of anti-osteoporotic drugs and risk of AF. No significant association was observed for any of the drugs under study. A decreased risk was observed among high adherent patients (PDC \> 80%) and current users of BPs and SR, but the results did not reach statistical significance \[BP, PDC \> 80%: odds ratio (OR) = 0.81, 95% confidence interval (CI): 0.56--1.16; current use: OR = 0.95, 95% CI: 0.81--1.11\].

###### 

AF study: use of anti-osteoporotic drugs and risk of atrial fibrillation: analysis of intensity of use (PDC) and role of time.

![](10.1177_2042098619838138-table3)

  --------------------------------------------------------------------------------------------------------------------------------------------------
                           Cases       Controls   OR\           CI 95%     OR\        CI 95%                               
                                                  crude                    adj                                             
  ------------------------ ----------- ---------- ------------- ---------- ---------- ------------------------- ---------- -------------------------
  **Bisphosphonates**      **477**     **1.7**    **1955**      **1.7**    **0.98**   **0.88** **-** **1.08**   **1.02**   **0.91** **-** **1.14**

  \<20%                    260         100.0      984           100.0      1.06       0.92-1.22                 1.07       0.92-1.25

  20--80%                  176         67.7       743           75.5       0.95       0.81-1.12                 1.00       0.84-1.2

  \>80%                    41          15.8       228           23.2       0.72       0.52-1.00                 0.81       0.56-1.16

  **Strontium ranelate**   **177**     **0.6**    **659**       **0.6**    **1.08**   **0.91** **-** **1.27**   **1.09**   **0.91** **-** **1.31**

  \<20%                    114         100.0      389           100.0      1.17       0.95-1.44                 1.12       0.89-1.42

  20--80%                  56          49.1       222           57.1       1.01       0.75-1.35                 1.11       0.81-1.54

  \>80%                    7           6.1        48            12.3       0.59       0.27-1.30                 0.63       0.28-1.46

  **Others**               **128**     **0.5**    **447**       **0.4**    **1.15**   **0.94** **-** **1.4**    **1.13**   **0.91** **-** **1.42**

  \<20%                    96          100.0      313           100.0      1.24       0.99-1.57                 1.21       0.93-1.56

  20--80%                  25          26.0       97            31.0       1.04       0.67-1.62                 1.08       0.66-1.77

  \>80%                    7           7.3        37            11.8       0.76       0.34-1.69                 0.88       0.36-2.17

  **Nonusers (ref)**       **27263**   **97.1**   **109144**    **97.1**   **1**      **-**                     **1**      **-**

                           Cases       Controls   OR\           CI 95%     OR\        CI 95%                               
                                                  crude                    adj                                             

                           *N*         \%         *N*           \%                                                         

  **Bisphosphonates**      **477**     **1.7**    **1955**      **1.7**    **0.98**   **0.88** **-** **1.08**   **1.02**   **0.91** **-** **1.14**

  current users            230         48.2       983           50.3       0.94       0.81-1.08                 0.95       0.81-1.11

  recent users             61          12.8       258           13.2       0.95       0.72-1.25                 0.99       0.73-1.34

  distant users            186         39.0       717           36.7       1.04       0.89-1.23                 1.13       0.94-1.35

  **Strontium ranelate**   **177**     **0.6**    **659**       **0.6**    **1.08**   **0.91** **-** **1.27**   **1.09**   **0.91** **-** **1.31**

  current users            61          34.5       983           149.2      0.66       0.67-1.17                 0.94       0.7-1.28

  recent users             23          13.0       258           39.2       0.94       0.59-1.47                 1.04       0.64-1.69

  distant users            93          52.5       717           108.8      1.3        1.03-1.64                 1.27       0.98-1.65

  **Others**               **128**     **0.5**    **447**       **0.4**    **1.15**   **0.94** **-** **1.4**    **1.13**   **0.91** **-** **1.42**

  current users            35          27.3       141           31.5       0.99       0.68-1.43                 1.05       0.7-1.59

  recent users             18          14.1       59            13.2       1.22       0.72-2.07                 1.08       0.6-1.96

  distant users            75          58.6       247           55.3       1.24       0.96-1.61                 1.18       0.88-1.58

  **Nonusers (ref)**       **27263**   **97.1**   **10,9144**   **97.1**   **1**      **-**                     **1**      **-**
  --------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for: diagnosis at enrolment, previous AMI, AF, cerebrovascular diseases, cardiomyopathy, rheumatic heart, previous PCI, cerebral revascularization procedures, Cancer, Lipid metabolism disturbances, COPD, hypertension, thyroid disease, cardiac therapy, antihypertensives, beta-adrenergic antagonist, calcium channel blockers, ACE inhibitors, lipid-modifying agents, oral anticoagulants, drugs used in diabetes, thyroid therapy.

ACE, acetylcholinesterase; AF: atrial fibrillation; AMI, acute myocardial infarction; CCV: acute cerebrovascular/cardiovascular events; CI, confidence interval; COPD, chronic obstructive pulmonary disease; OR, odds ratio; PCI, Percutaneous Coronary Intervention; PDC, proportion of days covered.

Compared with nonusers, patients with at least one prescription for BPs or SR showed an increased risk of subsequent acute CCV events (OR = 1.07, 95% CI: 1.03--1.12 and OR = 1.24, 95% CI: 1.16--1.32, respectively; [Table 4](#table4-2042098619838138){ref-type="table"}). As in the AF study, higher adherence (PDC \> 80%) was associated with a decreased risk of CCV events (OR = 0.81, 95% CI: 0.71--0.92 for BPs and OR = 0.71, 95% CI: 0.52--0.97 for SR). Accordingly, recent and distant users were at an increased risk with respect to current users.

###### 

CCV study: use of anti-osteoporotic drugs and risk of CCV outcomes: analysis of intensity of use (PDC) and role of time.

![](10.1177_2042098619838138-table4)

  ---------------------------------------------------------------------------------------------------------------------------------------------------
                           Cases         Controls   OR\          CI 95%     OR\        CI 95%                               
                                                    crude                   adj                                             
  ------------------------ ------------- ---------- ------------ ---------- ---------- ------------------------- ---------- -------------------------
  **Bisphosphonates**      **2967**      **1.9**    **11350**    **1.8**    **1.05**   **1.01** **-** **1.09**   **1.07**   **1.03** **-** **1.12**

  \<20%                    1585          53.4       5588         49.2       1.14       1.08-1.21                 1.13       1.07-1.20

  20--80%                  1115          37.6       4312         38.0       1.04       0.98-1.11                 1.06       0.99-1.13

  \>80%                    267           9.0        1450         12.8       0.74       0.65-0.85                 0.81       0.71-0.92

  **Strontium ranelate**   **1156**      **0.7**    **3939**     **0.6**    **1.18**   **1.10** **-** **1.26**   **1.24**   **1.16** **-** **1.32**

  \<20%                    762           65.9       2276         57.8       1.35       1.24-1.47                 1.37       1.26-1.49

  20--80%                  347           30.0       1350         34.3       1.03       0.92-1.16                 1.10       0.97-1.24

  \>80%                    47            4.1        313          7.9        0.60       0.44-0.82                 0.71       0.52-0.97

  **Others**               **578**       **0.4**    **2410**     **0.4**    **0.96**   **0.88** **-** **1.06**   **0.99**   **0.90** **-** **1.09**

  \<20%                    416           72.0       1689         70.1       0.99       0.89-1.11                 1.02       0.92-1.14

  20--80%                  126           21.8       531          22.0       0.96       0.79-1.16                 0.99       0.81-1.20

  \>80%                    36            6.2        190          7.9        0.75       0.53-1.08                 0.79       0.55-1.13

  **Nonusers (ref)**       **152032**    **96.8**   **609376**   **97.0**   **1**      **-**                     **1**      **-**

                           Cases         Controls   OR\          CI 95%     OR\        CI 95%                               
                                                    crude                   adj                                             

                           *N*           \%         *N*          \%                                                         

  **Bisphosphonates**      **2967**      **1.9**    **11350**    **1.8**    **1.05**   **1.01** **-** **1.09**   **1.07**   **1.03** **-** **1.12**

  current users            491           16.5       247          2.2        0.97       0.91-1.03                 0.99       0.94-1.06

  recent users             302           10.2       673          5.9        1.19       1.06-1.33                 1.25       1.11-1.40

  distant users            2174          73.3       10430        91.9       1.12       1.05-1.20                 1.12       1.05-1.20

  **Strontium ranelate**   **1156**      **0.7**    **3939**     **0.6**    **1.18**   **1.10** **-** **1.26**   **1.24**   **1.16** **-** **1.32**

  current users            183           15.8       101          2.6        0.97       0.87-1.09                 1.03       0.92-1.15

  recent users             83            7.2        174          4.4        1.10       0.92-1.32                 1.18       0.97-1.42

  distant users            890           77.0       3664         93.0       1.40       1.28-1.54                 1.46       1.32-1.60

  **Others**               **578**       **0.4**    **2410**     **0.4**    **0.96**   **0.88** **-** **1.06**   **0.99**   **0.90** **-** **1.09**

  current users            67            11.6       44           1.8        0.89       0.75-1.05                 0.91       0.76-1.08

  recent users             50            8.7        67           2.8        1.04       0.82-1.32                 1.07       0.83-1.36

  distant users            461           79.8       2299         95.4       0.99       0.88-1.12                 1.03       0.91-1.16

  **Nonusers (ref)**       **15,2032**   **96.8**   **609376**   **97.0**   **1**      **-**                     **1**      **-**
  ---------------------------------------------------------------------------------------------------------------------------------------------------

Adjusted for: diagnosis at enrolment, previous AMI, AF, cerebrovascular diseases, heart failure, blood disorders, vascular diseases, previous PCI, cerebral revascularization procedures, conduction disturbances, thyroid disease, chronic renal disease, cardiac therapy, antihypertensives, beta-adrenergic antagonist, calcium channel blockers, ACE inhibitors, lipid-modifying agents, oral anticoagulants, drugs used in diabetes, thyroid therapy.

ACE, acetylcholinesterase; AF: atrial fibrillation; AMI, acute myocardial infarction; CCV: acute cerebrovascular/cardiovascular events; CI, confidence interval; OR, odds ratio; PCI, Percutaneous Coronary Intervention; PDC, proportion of days covered.

Sensitivity analyses confirmed our findings: matching on the condition at enrolment, led to almost identical estimates for all the three exposures measures and for both outcomes. For example, ever use of BPs corresponded to an OR for AF of 0.94 (95% CI: 0.85--1.04) and an OR of 0.80 (95% CI: 0.57--1.12).

Discussion {#section15-2042098619838138}
==========

Overall, two nested case-control studies were performed to evaluate whether anti-osteoporotic drug use increases the risk of subsequent AF or CCV events in elderly patients with previous CCV disease and can thus be considered inappropriate for this population.

The present study does not provide evidence for an increased risk of AF or CCV events; moreover, more adherent patients showed a decreased risk of either AF or CCV.

These findings are in line with those from several randomized controlled trials and observational studies, especially with population-based studies from Denmark and the United Kingdom^[@bibr23-2042098619838138][@bibr24-2042098619838138][@bibr25-2042098619838138]--[@bibr26-2042098619838138]^ and support indications to continue using BPs as a first-line treatment for osteoporosis, keeping patients at high AF and CCV risk closely monitored.^[@bibr35-2042098619838138]^ On the contrary, a previous multicentre study using data from Italy suggested an increased risk of AF among patients using BPs compared with those who had stopped BP therapy for more than 365 days before the event.^[@bibr21-2042098619838138]^ An increased AF risk was also reported from a recently published observational study from Taiwan, which yet is not strictly comparable with our study, as BPs were compared to vitamin D rather than to other treatments, and the findings were based on small numbers.^[@bibr22-2042098619838138]^

On investigating the effect of exposure duration, the lack of association between BPs or SR and AF or CCV persisted. This might be partly due to a healthy adherer effect: patients with higher adherence are likely to have healthier lifestyle habits. Another possible explanation is that clinicians are more likely to continue prescribing drugs with a long-term treatment effect such as anti-osteoporotic drugs in persons with a long life-expectancy and fewer contraindications. Moreover, long-term users are typically those patients that tolerate the drug well. Similar findings were reported from a study on the association of BP use and valvulopathy, where a protective effect was indicated with prolonged use.^[@bibr39-2042098619838138]^ Also, a Danish study reported an increased AF risk after discontinuation of BPs, which is intuitive of selective de-prescribing.^[@bibr20-2042098619838138]^ A similar study on heart failure in patients treated with BPs found a dose-dependent risk reduction among alendronate users.^[@bibr40-2042098619838138]^ Similarly, a cohort study comparing alendronate with raloxifene found a lower risk of cardiovascular disease in patients receiving higher doses of alendronate.^[@bibr41-2042098619838138]^ In another cohort an inverse dose-response relationship between exposure to alendronate and the risk of AMI was detected and the authors concluded that this finding 'precludes that alendronate per se increases the risk of AMI and atherosclerosis'.^[@bibr42-2042098619838138]^

When comparing results between studies, one must bear in mind the differences in the study populations. For example, the most recent observational study compared BP treatment *versus* vitamin D and none, rather than different active BP treatments^[@bibr22-2042098619838138]^ (Yang). Our cases and controls were part of a cohort of patients with pre-existing cardiovascular conditions, and this may lower external validity, that is, results may not be fully comparable with those reported by other researchers. Still, the aim of the present study was to identify potentially inappropriate drug treatment in this population and all enrolees were well characterised for the underlying CCV risk.

Another critical aspect when comparing studies arises from differences in exposure definition, which may have an important impact on the results. In our study, adherence was simulated with DDDs because our data do not provide information on individual dosages or patient's compliance. We used different exposure measures, also accounting for the effect of timing and treatment duration.

Osteoporosis in our administrative claims databases is likely to be under-reported, as this condition does not require hospital admission as a primary cause and is unlikely to be recorded on hospital discharge as a secondary cause. Consequently, osteoporosis diagnosis was not among the inclusion criteria, but we considered the osteoporosis drugs as a sufficient proxy for having the disease. We therefore included SR and other anti-osteoporotic drugs for comparison, also bearing in mind that an association between osteoporosis itself and cardiovascular disease has been suggested.^[@bibr43-2042098619838138]^ Another limit is the fact, that we could not account for vitamin D treatment, as this is not perfectly retrievable in our databases, and that numbers were too small to analyse single BP active agents separately.

The role of the CCV condition at enrolment of the patient was dealt with through two different approaches, namely including the condition as a covariate in the logistic regression model, and performing sensitivity analysis in which cases and controls were matched on their underlying CCV condition. Both approached produced overlapping results. Residual confounding is an issue in all observational studies, especially when based on administrative healthcare data, which do not comprise detailed clinical data or lifestyle information (e.g. body mass index and smoking). We tried to limit confounders by using a new-user design, matching cases with up to four controls, restricting the study population, and performing sensitivity analysis, which produced robust results. For example, we restricted the study population to BP users, comparing different levels of adherence, to rule out the risk of indication bias. Furthermore, in our study we did not have information regarding the indication of drug use, that is, a diagnosis of osteoporosis. Therefore, we compared the risk of the study outcomes not only between users and nonusers of BPs, but also between different osteoporotic treatments, as a proxy for the condition itself, in order to reduce the role of the underlying condition.

Conclusion {#section16-2042098619838138}
==========

The present multicentre study was based on a large population of elderly patients in five different geographic areas in Italy accounting for about 21 million people, that is, about 35% of the overall Italian population. We found no evidence of an increased risk of AF in patients treated with oral BPs or SR compared with nonusers. BP and SR use was associated with an increased risk of CCV, which disappeared with high adherence, suggesting a healthy adherer effect. According to the results of our study, osteoporosis treatment with BPs cannot be considered inappropriate in elderly patients, but they should be carefully monitored.
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